Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF -6.86%60 5-Year Share Buyback Ratio is -13.60 as of Jun. 2026. GuruFocus rates ZLDPF with a GF Score™ of 60/100 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,131 Biotechnology companies, Zealand Pharma AS ranks worse than 57.91% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Zealand Pharma AS's current 5-Year Share Buyback Ratio was -13.60%.
ZLDPF's 5-Year Share Buyback Ratio is ranked worse than 57.91% of 1131
companies
in the Biotechnology industry
Industry Median: -10.3
vs ZLDPF: -13.60
Zealand Pharma AS (OTCPK:ZLDPF) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Zealand Pharma AS 5-Year Share Buyback Ratio Related Terms
ZLDPF vs VRTX, REGN, RVMD: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 5-Year Share Buyback Ratio falls into.
Zealand Pharma AS 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -13.60 mean?
Zealand Pharma AS (ZLDPF) has a 5-Year Share Buyback Ratio of -13.60 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #655 out of 1131 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Zealand Pharma AS's 5-Year Share Buyback Ratio too high?
Zealand Pharma AS's current 5-Year Share Buyback Ratio is -13.60. Based on the distribution chart, Zealand Pharma AS ranks #655 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 5-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #655 out of 1131 companies for 5-Year Share Buyback Ratio. This places Zealand Pharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Zealand Pharma AS and its competitors. Zealand Pharma AS's current 5-Year Share Buyback Ratio is -13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The current 5-Year Share Buyback Ratio is -13.60. Zealand Pharma AS's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current 5-Year Share Buyback Ratio is -13.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
60GF Score
Get the complete analysis for ZLDPF
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
